To derive and validate simple screens of 2 to 4 questions to identify cognitive impairment.
The derivation and validation of the Ottawa 3D and Ottawa
3DY three-and four-question screens for cognitive impairment
Cognitive impairment is a common presenting symptom of a number of increasingly prevalent conditions such as dementia, delirium and, occasionally, depression. It is predicted that the prevalence of dementia in North America will increase from 3.4 million people in 2001 to 5.1 million in 2020 and in Western Europe will increase from 4.9 million in 2001 to 6.9 million in 2020. 1 Worldwide it is estimated that 24.3 million people currently suffer from dementia and that, with an estimated 4.6 million new cases every year, the prevalence will increase to 42.3 million in 2020. 1 Depression and delirium can also be anticipated to rise correspondingly as persons with dementia are at increased risk for these conditions.
Early detection of delirium and depression (presenting with cognitive symptoms) may limit the duration of the disorders by triggering earlier treatment. Earlier detection of cognitive impairment of any etiology may benefit patients and families in several ways.
It advances the time when they seek assistance, perhaps prior to the development of avoidable stress and related medical disorders for the caregivers. It stimulates planning for the future such as establishing power of attorney, wills and advanced directives while patients are still capable of contributing to decisions. Other benefits include addressing safety issues such as the person's ability to live independently, their wandering risk, fire risk, medication error risk and fitness to drive in order to prevent avoidable morbidity and mortality. 2 There is also some evidence that early initiation of pharmacotherapy for dementia may prolong independence and reduce costs by delaying nursing home placement. 3 For these reasons, and even in the absence of a cure, there is a growing consensus that persons over age 75 should be routinely screened for cognitive impairment. [4] [5] [6] [7] Previous research has demonstrated that physicians miss cognitive impairment in over 50% of cases: the gestalt method (based on general impression or the physician's intuition) is inadequate. [8] [9] [10] [11] [12] [13] Plausibly, early or mild cases may be missed while more advanced cases are preferentially detected. Formal screening is not routinely employed.
Only 39% of Australian general practitioners (GPs) and 26% of Canadian GPs regularly screen for dementia. 4, 14 In order to increase screening rates we must understand the barriers to screening. The time to administer screening tests is often cited as a barrier, especially in high volume specialties with marked time pressures such as emergency medicine, general practice or family medicine. 4, 15, 16 Here, the Mini-Mental State Examination (MMSE) 17 has been described as impractical as it takes 10 minutes to administer, 1, 18, 19 and the need for shorter screening instruments has been highlighted. 4 Another barrier to routine screening is the complexity of administration and scoring. This touches on Feinstein's concept of 'clinical sensibility' 20, 21 -whether a tool is clinically reasonable, quick and simple to apply, score and interpret, and whether it suggests a course of action (i.e. categorizes patients rather than merely providing probabilities).
Clinical sensibility demands that tools be designed with the realities of busy front-line clinical care in mind. While not explicitly employing the term, Brodaty et al. clearly incorporated the notion of clinical sensibility in their excellent review of dementia screening instruments. 22 Screening tools often focus on specific diagnoses such as delirium 23 , depression 24 or dementia. 16, 22 However, in first-contact care settings there may be value in also using very simple screens for the more general symptom of cognitive impairment rather than (or before) applying screens for the more specific causes of impairment, such as delirium, depression, or dementia. Because a screening tool for one of these specific disorders may miss the presence of the other two it may prove optimal to first screen for the common denominator amongst these disorders -cognitive impairment. Screening for cognitive impairment and screening for specific causes are not necessarily mutually exclusive, but may represent complementary approaches that can enhance clinical care.
A number of tools to identify impaired cognition exist. These have been reviewed by B Lorentz, 16 Burns, 18 McDowell, 19 and Brodaty et al. 22 The Lorentz et al 16 and Brodaty et al, 22 after performing independent in-depth assessments of psychometric properties and clinical sensibility features, recommended the same three instruments for general practitioners to screen for dementia: the General Practitioner Assessment of Cognition (GPCOG) 32 , the Mini-Cog, 33 and the Memory Impairment Screen (MIS). 34 Despite the fact that these tests take 3 to 4½ minutes to apply, they are not routinely used on a widespread basis most likely because they may still be too long and too difficult to score for many clinicians to consider applying them on a routine daily basis.
In the search for even shorter screening tools, Siu has shown that no single cognitive question is adequate as a screen for cognitive impairment. 35 He concluded that a brief combination of screening questions could best determine the need for additional mental status examination.
The goal of our study was to determine if subsets of two, three or four cognitive questions could demonstrate adequate sensitivity and specificity to justify further validation research. Some researchers have pursued this line of inquiry using multivariate analysis, producing predictive formulae. We feel it is unrealistic to expect physicians to routinely incorporate complex equations into clinical practice. This contravenes the principle of clinical sensibility, and therefore multivariable equations are rarely, if ever, used in routine front-line clinical care. We decided a priori that while we would use multivariate analyses to select cognitive questions, the final product of this research would not require any calculation.
METHODS

I. Sample and Diagnostic Classification
The data analyzed were collected as part of the Canadian Study of Health and Aging (CSHA, www.csha.ca ), a national, multicentre epidemiological study of dementia. who supplied historical information via the CAMDEX. 38 The study diagnosis was established at a clinical consensus meeting involving physician, neuropsychologist and nurse. Subjects were classified as having no cognitive impairment, cognitive impairment but not dementia, or dementia. Dementia was rated as mild, moderate or severe and an etiological diagnosis was made.
As physicians do not require screens to detect persons with severe cognitive impairment, and as the inclusion of severely cognitively impaired participants in the analysis would artificially inflate sensitivity and specificity, the data from persons with severe cognitive impairment were removed. The institutionalized sample was not included as it may represent a spectrum of disease not encountered in the community. Other exclusion criteria included primary language other than English, and deficits in hearing or vision severe enough to affect cognitive testing.
II. Analysis
Diagnoses were collapsed into cognitively normal vs. cognitively impaired. As we were developing a general cognitive screen, the latter included persons with any etiology of cognitive impairment including ethanol induced impairment, cerebrovascular disease, pre-clinical dementias (some of whom would now be diagnosed as having mild cognitive impairment), etc. Individual cognitive questions were drawn from the 3MS, which provides a larger selection of items than the 30-point MMSE, although virtually all of the MMSE items are embedded in the 3MS. To maximize practicality, we discarded questions that required the use of paper and pen, cue cards or props, and those requiring more than 30 seconds to answer. We simplified scores for each item into a dichotomous score of right or wrong to promote ease of recall and scoring.
Using chi-square (χ 2 ) univariate analyses of the dichotomously scored questions, we tested the association between each question and cognitive impairment. Questions showing statistically significant associations were then entered into a forward logistic regression algorithm, using cognitive status (i.e. impaired vs. normal) as the dependent variable.
A characteristic of standard logistic regression algorithms is that they do not maximize either sensitivity or specificity, but instead attempt to maximize the overall correct classification -a combination of sensitivity and specificity. This could restrict the ability of regression analyses to yield maximally sensitive or maximally specific screens. To overcome this limitation, we employed a 'logistic regression serial weighting algorithm'
by successively weighted cases (cognitively impaired) from 1 to 10 while keeping cognitively normal controls fixed at a weight of 1 in order to generate increasingly sensitive but less specific logistic regression equations. We then serially weighted the controls from 1 to 10 while keeping cases fixed at a weight of 1 in order to generate increasingly specific but less sensitive equations.
Simple scales of equally-weighted questions were created using the first 2, The initial screening tools were derived from the CSHA-1. Promising combinations of cognitive questions with sensitivity and specificity similar to those of the full 3MS were selected for validation in data from the second CSHA wave performed in 1996-1997 of surviving CSHA-1 participants. This involved testing the sensitivity and specificity of the brief screening scales developed from the CSHA-1 data in the equivalent data collected five years later, at CSHA-2.
RESULTS:
The selection criteria generated 1560 CSHA-1 community participants who had undergone full medical and neuropsychological evaluation with cognitive status determined at a consensus conference (958 were mildly to moderately cognitively impaired and 602 were not cognitively impaired). The mean age was 79.5 years old (SD 6.7) with 60.8% of participants being female. Twenty-four percent had completed high school and 10% had additional post-secondary education. The mean 3MS score was 76.8, which translated into a calculated MMSE score between 23 and 24.
The complete 3MS had a sensitivity of 84% and specificity of 62% in distinguishing between these two groups, using a cutoff score between 77 and 78 on the 100-point scale.
Based on practical clinical sensibility criteria, 21 candidate questions were selected for analysis of association with cognitive impairment. Consistent with Siu's findings, 35 Chisquare analyses demonstrated that no single question had both sensitivity and specificity approaching those of the complete 3MS. The two most promising single questions were;
'Count from 5 to 1 backwards' and 'Spell WORLD backwards' (Table 1) . Eighteen questions demonstrated a statistically significant association with cognitive status. Since the three non-significant questions were close in terms of sensitivities and specificities to the other questions, we ran the logistic regression analyses with and without the three non-significant variables. Including the non-significant variables did not change the results of multivariate analyses.
The serially weighted logistic regression analyses yielded 8 scales ranging from 2 to 4 questions in length ( Table 2 ). The two tests whose psychometric properties most closely resembled those of the complete 3MS in the CSHA-1 derivation data were set 3-1 (which we named the Ottawa 3D test: Day, Date, DLROW) and set 4-1 (the Ottawa 3DY test:
Day, Date, DLROW, Year). Taking one or more errors to indicate cognitive impairment,
the Ottawa 3D test demonstrated a sensitivity of 80% and a specificity of 56%. With a cutoff of one or more errors the Ottawa 3DY test demonstrated a sensitivity of 82% and a specificity of 55%.
The sensitivity and specificity of the Ottawa 3D and 3DY in the CSHA-2 validation database are shown in Table 3 . The final results were: Ottawa 3D sensitivity = 76% and specificity = 62%; Ottawa 3DY sensitivity = 80% and specificity = 61%).
DISCUSSION:
In the clinical care of persons at risk for dementia and delirium, it is likely misguided to believe that one cognitive screening tool will be acceptable to all clinicians on all occasions in all settings. Rather, we should respect physician heterogeneity and the rapidly changing and challenging clinical scenarios they face. Clinicians should have a range of useful tools to draw on depending on the demands of the circumstance -a cognitive screening toolbox. Some physicians will want screening tools of varying length and complexity to detect general cognitive impairment while others will want a range of tools to screen for specific diagnoses such as dementia, delirium or depression. Some may resist screening altogether, feeling their general impression is adequate. The latter group might become more receptive to formal screening if a well-stocked toolbox of cognitive screening tests were readily available (perhaps with downloadable forms on national medical association or dementia websites).
The shortest of the previously published tests requires several minutes to apply and would likely be too complex for most busy MDs to readily recall. With this in mind, our intention was not to develop screening tools to compete with existing tests but rather to add to the armamentarium of practical or clinically sensible tests available to cliniciansto augment their cognitive screening toolbox -by exploring the possibility of even shorter tests. The Ottawa 3D and Ottawa 3DY tests performed as well as the 3MS and, due to their ease of recall and scoring, minimize barriers to screening and thereby maximize the feasibility of widespread application.
Some have questioned why we attempted to match the sensitivity and specificity of the 3MS rather than aiming for 100% sensitivity and 100% specificity. Cognitive decline is a continuum that is conveniently, but somewhat arbitrarily, divided into those with normal cognition and those with cognitive impairment. Because of individual variations, test scores for these groups commonly overlap ( Figure 1A ), so reducing sensitivity and specificity. Due to commonly overlapping distributions of test scores for persons with normal cognition vs. those with cognitive impairment (Fig. 1A) there is always a tradeoff between sensitivity and specificity when employing dichotomization (as sensitivity increases specificity decreases -see Figure 1C and Tables 2 and 3) . Although less apparent, this reciprocal relationship between sensitivity and specificity is also reflected in standard ROC curves (Fig 1D) . The result is that no cognitive test can ever simultaneously approach perfect sensitivity and specificity. It is therefore more informative to judge the Ottawa 3D and 3DY tests against existing validated tests such as the 3MS than against an unattainable ideal.
Although they performed well in comparison to the 3MS, the Ottawa 3D and 3DY tests are not ready for immediate clinical use. This study should be viewed as an exploratory data analysis with a preliminary validation, with several limitations that mandate that the findings be more thoroughly validated before widespread clinical use is recommended.
The limitations include the fact that the derivation (CSHA-1) and validation (CSHA-2) databases are not completely independent, and the cognitive questions studied (including the entire 3MS) formed a small part of the data employed to achieve a consensus diagnosis of cognitive status. These factors can artificially inflate both sensitivity and specificity.
Since those who screened positive for cognitive impairment (plus a random subset of those who screened negative) were selected for full clinical evaluation, verification bias (a.k.a. work-up bias or sequential-ordering bias) exists and the risk that the sensitivities and specificities reported are inaccurate must be recognized. Because of their shared content, it is likely that any verification bias will act in a similar fashion on the Ottawa 3D, 3DY and 3MS. If so, then the comparison between them should remain constant in other datasets (i.e. the psychometric properties of the Ottawa 3D and 3DY should remain close to those of the 3MS). More extensive validation research is required to support or refute this possibility. Consequently, we cannot definitively predict the psychometric properties of the tests in actual clinical practice and limit our conclusion to stating that the Ottawa 3D and 3DY screens appear to have psychometric properties similar to the complete 3MS, a test that has been found to be superior to the MMSE, and that these new tests therefore merit further study.
This study has several strengths that are worth highlighting. The Ottawa 3D and 3DY
tests are easy to recall, apply and score and hence can be applied anywhere and at any The full potential value of the Ottawa 3D and 3DY tests can best be understood in the context of a serial testing approach whereby short tests requiring very little time are applied to large sets of patients and longer tests are applied to increasingly smaller subsets of patients that are selected by the shorter tests (Fig 2) . This approach improves efficiency by increasing case finding while minimizing time investment. Due to selection of increasingly smaller subsets of patients, the sensitivities and specificities of secondary and tertiary screens would need to be reevaluated in the context of the screening algorithms.
Sequential screening approaches can be further refined to maximize efficiency. When employing a single cut-off (i.e. dichotomization), screening and diagnostic tests often demonstrate limited psychometric properties (e.g. poor sensitivity, specificity, positive predictive value, and / or negative predictive value) due to the frequent overlap between the distributions of test results of persons who are cognitively normal and those with impairment ( Fig 1A) . Trichotomization, employing two cut-points, can sometimes overcome the limited sensitivities and specificities generated by dichotomizationemploying a single cut-point ( Figure 1B) . By combining the sequential testing and trichotomization approaches we can develop increasingly efficient screening and casefinding algorithms as depicted in Figure 2 . Very simple and rapid screening tools such as the Ottawa 3D and 3DY tests that can be readily applied to large numbers of patients without disrupting clinical practice could serve as triggers for such high efficiency screening algorithms.
The concept of 'serial trichotomization' is not new to the field of dementia as it has been recommended in the assessment of fitness-to-drive in dementia. 41 Dementia researchers should consider reanalyzing neuropsychological tests, biomarkers and neuroimaging using serial trichotomization to determine if this approach will generate more promising sensitivities and specificities.
CONCLUSIONS:
The Ottawa 3D and 3DY tests are promising cognitive screens that should be simple enough to employ to promote widespread use. While the results are very promising they must be validated in the target group for which the tests are intended before we will know the true sensitivity, specificity and utility of the tests. Despite these cautionary notes the findings of this study are very promising and, if the derived tests live up to their promise in future validation studies, we would have a major addition to the armamentarium of practicing clinicians.
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